Bellicum Pharmaceuticals Inc (BLCM) was Initiated by Raymond James to “Outperform”. Raymond James advised their investors in a research report released on Dec 1, 2016.
Many Wall Street Analysts have commented on Bellicum Pharmaceuticals Inc. Bellicum Pharmaceuticals Inc was Initiated by Ladenburg Thalmann to “Buy” on Nov 30, 2016. Cantor Fitzgerald Initiated Bellicum Pharmaceuticals Inc on Nov 2, 2016 to “Buy”, Price Target of the shares are set at $32.
On the company’s financial health, Bellicum Pharmaceuticals Inc reported $-0.66 EPS for the quarter, missing the analyst consensus estimate by $ -0.03 based on the information available during the earnings call on Nov 9, 2016. Analyst had a consensus of $-0.63. The company had revenue of $.11 million for the quarter, compared to analysts expectations of $.09 million. The company’s revenue was up 90.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.51 EPS.
Bellicum Pharmaceuticals Inc opened for trading at $18.96 and hit $19.8232 on the upside on Tuesday, eventually ending the session at $19.16, with a gain of 1.64% or 0.31 points. The heightened volatility saw the trading volume jump to 3,56,879 shares. Company has a market cap of $519 M.
In a different news, on Nov 29, 2016, Alan A Musso (CFO and Treasurer) sold 29,300 shares at $19.85 per share price. According to the SEC, on Sep 23, 2016, David M. Spencer (Chief Scientific Officer) sold 16,500 shares at $19.97 per share price. On Sep 23, 2016, Kevin M. Slawin (Chief Technology Officer) sold 23,416 shares at $20.08 per share price, according to the Form-4 filing with the securities and exchange commission.
Bellicum Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing cellular immunotherapies for various forms of cancer including hematological cancers and solid tumors as well as orphan inherited blood disorders. The Company is using its chemical induction of dimerization (CID) technology platform to engineer and then control components of the immune system in real time. The Company is developing next-generation product candidates in the areas of cellular immunotherapy including hematopoietic stem cell transplantation (HSCT) chimeric antigen receptors (CAR) T cells therapy and dendritic cell vaccines. The Company’s product candidates include BPX-501 BPX-201 BPX-401 BPX-601 and BPX-701. It is also engaged in other development programs such as CIDeCAR for the treatment of solid tumors and CaspaCIDe TCR for the treatment of hematological cancers.